180 related articles for article (PubMed ID: 10543325)
1. Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment.
Altun B; Erdem Y; Usalan C; Arici M; Haznedaroglu IC; Yasavul U; Turgan C; Caglar S; Kirazli S
Clin Nephrol; 1999 Oct; 52(4):230-8. PubMed ID: 10543325
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3.
Stefanovic V; Mitić-Zlatkovic M; Radivojevic J; Vlahovic P
Ren Fail; 2005; 27(3):283-8. PubMed ID: 15957544
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin.
Tuzcu A; Bahceci M; Yilmaz E; Bahceci S; Tuzcu S
Horm Metab Res; 2004 Oct; 36(10):716-20. PubMed ID: 15523598
[TBL] [Abstract][Full Text] [Related]
5. Soluble transferrin receptor is correlated with erythropoietin sensitivity in dialysis patients.
Daschner M; Mehls O; Schaefer F
Clin Nephrol; 1999 Oct; 52(4):246-52. PubMed ID: 10543327
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
7. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
8. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes.
Descamps-Latscha B; Herbelin A; Nguyen AT; Roux-Lombard P; Zingraff J; Moynot A; Verger C; Dahmane D; de Groote D; Jungers P
J Immunol; 1995 Jan; 154(2):882-92. PubMed ID: 7814891
[TBL] [Abstract][Full Text] [Related]
9. Elevated expression of CD23 on peripheral blood B lymphocytes from patients with bullous pemphigoid: correlation with increased serum IgE.
Inaoki M; Sato S; Takehara K
J Dermatol Sci; 2004 Jun; 35(1):53-9. PubMed ID: 15194147
[TBL] [Abstract][Full Text] [Related]
10. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating antierythropoietin antibodies in patients with end stage renal disease on regular hemodialysis.
El-Din MM; Attia FM; Labib SM; Omar W
Int J Lab Hematol; 2010 Jun; 32(3):336-43. PubMed ID: 19703235
[TBL] [Abstract][Full Text] [Related]
12. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
13. Serum erythropoietin levels and their correlation with the erythropoietic system in hemodialysis patients and renal allograft recipients.
Khosroshahi HT; Shoja MM; Tubbs RS; Estakhri R; Ardalan MR
Transplant Proc; 2007 May; 39(4):1051-3. PubMed ID: 17524889
[TBL] [Abstract][Full Text] [Related]
14. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis.
Molica S; Levato D; Dell'Olio M; Matera R; Minervini M; Dattilo A; Carotenuto M; Musto P
Haematologica; 1996; 81(5):428-33. PubMed ID: 8952156
[TBL] [Abstract][Full Text] [Related]
15. B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis.
Raskova J; Ghobrial I; Czerwinski DK; Shea SM; Eisinger RP; Raska K
Arch Intern Med; 1987 Jan; 147(1):89-93. PubMed ID: 3492183
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
17. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma.
Schroeder JR; Saah AJ; Hoover DR; Margolick JB; Ambinder RF; Martinez-Maza O; Breen EC; Jacobson LP; Variakojis D; Rowe DT; Armenian HK
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):979-84. PubMed ID: 10566552
[TBL] [Abstract][Full Text] [Related]
19. Immune response in hemodialysis patients: is there any difference when low and high iPTH levels are compared?
Tzanno-Martins C; Futata E; Jorgetti V; Duarte AJ
Clin Nephrol; 2000 Jul; 54(1):22-9. PubMed ID: 10939753
[TBL] [Abstract][Full Text] [Related]
20. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
